We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
TRUP Lags Industry, Trades at a Premium: What Should Investors Know?
Read MoreHide Full Article
Key Takeaways
Trupanion shares are down 36.5% YTD, trailing its industry, sector and the S&P 500 composite.
Rising veterinary and claims costs, slower pet growth and underwriting pressure have weighed on TRUP.
Trupanion expects 2026 revenues of $1.584-$1.601B and adjusted operating income of $176-$184M.
Shares of Trupanion Inc. (TRUP - Free Report) have lost 36.5% year to date, underperforming its industry, sector and the Zacks S&P 500 composite in the same time frame. The dip likely reflects slower pet/puppy growth, rising veterinary and claims costs and pressure on underwriting margins.
This pet insurer provides insurance for cats and dogs in the United States, Canada, Continental Europe and Australia. It operates in a total addressable market worth more than $34.1 million, which is a large but underpenetrated market. Trupanion is well-poised to grow, courtesy of increased focus on pets’ health and well-being by pet parents, product launches, extended operating boundaries and a solid capital position.
TRUP vs Industry, Sector, S&P YTD
Image Source: Zacks Investment Research
Shares of Lemonade Inc. (LMND - Free Report) , another seller of pet insurance, have lost 36.6% year to date while those of Root Inc. (ROOT - Free Report) , a technology-oriented insurance company seeking growth through specialized underwriting and digital customer acquisition, have lost 36.2% in the same time frame.
TRUP Shares Are Expensive
The stock is overvalued compared with its industry. It is currently trading at a price-to-book multiple of 2.5, higher than the industry average of 1.62 but lower than the median of 4.23 over the past three years. It has a Value Score of C.
Image Source: Zacks Investment Research
The premium likely reflects a high-growth, recurring-revenue subscription business and scope for expanded market penetration.
TRUP shares are more expensive than ROOT but cheaper than LMND.
The Case for TRUP Stock
Trupanion has built a differentiated business model around high customer retention, recurring subscription revenues and a proprietary technology platform. Its direct-pay software enables participating veterinary hospitals to receive claim payments at checkout, improving the customer experience while strengthening relationships with veterinary partners.
The company continues to benefit from strong monthly retention, a growing enrolled-pet base, and rising average revenue per pet (ARPU), supporting consistent mid-teens revenue growth. As veterinary costs continue to rise faster than consumer discretionary income, disciplined pricing remains essential to sustaining growth while keeping pet insurance accessible.
International expansion represents another key growth opportunity. Under its five-year strategy, Trupanion has expanded into Europe, where relatively low pet-insurance penetration provides substantial long-term potential. As the subscriber base scales, greater operating leverage could support margin expansion and stronger free cash flow.
Trupanion is also broadening its addressable market through products such as Chewy and Aflac, which target lower- and mid-ARPU segments, alongside Firkin, Phi Direct, and offerings designed for continental Europe. The company has further expanded its technology platform through a branded offering and partnerships with automation providers in Germany and Switzerland.
With a strong capital position and solid operating performance, Trupanion can continue investing in product innovation and international expansion.
Optimistic Growth Estimates for TRUP
The Zacks Consensus Estimate for 2026 revenues and earnings indicates year-over-year improvement of 10.5% and 40%, respectively. The consensus estimate for 2027 revenues and earnings indicates year-over-year improvement of 8.7% and 10.6%, respectively. TRUP has a Growth Score of A.
Image Source: Zacks Investment Research
For 2026, the company expects revenues of $1.584-$1.601 billion, with the midpoint implying approximately 14% year-over-year growth. Adjusted operating income is expected in the range of $176-$184 million, representing about 19% growth at the midpoint.
Muted Analyst Sentiment on TRUP
The consensus estimate for 2026 and 2027 earnings witnessed no movement in the last 30 days.
The consensus estimates for LMND’s 2026 and 2027 earnings have witnessed no movement in the last 30 days. The same holds true for ROOT.
Parting Thoughts on TRUP Shares
TRUP is poised to grow in the fast-growing pet insurance market as pet ownership continues to increase and veterinary care costs rise. Its VGM Score of A instills confidence.
View the Zacks #1 Rank List
Image: Bigstock
TRUP Lags Industry, Trades at a Premium: What Should Investors Know?
Key Takeaways
Shares of Trupanion Inc. (TRUP - Free Report) have lost 36.5% year to date, underperforming its industry, sector and the Zacks S&P 500 composite in the same time frame. The dip likely reflects slower pet/puppy growth, rising veterinary and claims costs and pressure on underwriting margins.
This pet insurer provides insurance for cats and dogs in the United States, Canada, Continental Europe and Australia. It operates in a total addressable market worth more than $34.1 million, which is a large but underpenetrated market. Trupanion is well-poised to grow, courtesy of increased focus on pets’ health and well-being by pet parents, product launches, extended operating boundaries and a solid capital position.
TRUP vs Industry, Sector, S&P YTD
Image Source: Zacks Investment Research
Shares of Lemonade Inc. (LMND - Free Report) , another seller of pet insurance, have lost 36.6% year to date while those of Root Inc. (ROOT - Free Report) , a technology-oriented insurance company seeking growth through specialized underwriting and digital customer acquisition, have lost 36.2% in the same time frame.
TRUP Shares Are Expensive
The stock is overvalued compared with its industry. It is currently trading at a price-to-book multiple of 2.5, higher than the industry average of 1.62 but lower than the median of 4.23 over the past three years. It has a Value Score of C.
Image Source: Zacks Investment Research
The premium likely reflects a high-growth, recurring-revenue subscription business and scope for expanded market penetration.
TRUP shares are more expensive than ROOT but cheaper than LMND.
The Case for TRUP Stock
Trupanion has built a differentiated business model around high customer retention, recurring subscription revenues and a proprietary technology platform. Its direct-pay software enables participating veterinary hospitals to receive claim payments at checkout, improving the customer experience while strengthening relationships with veterinary partners.
The company continues to benefit from strong monthly retention, a growing enrolled-pet base, and rising average revenue per pet (ARPU), supporting consistent mid-teens revenue growth. As veterinary costs continue to rise faster than consumer discretionary income, disciplined pricing remains essential to sustaining growth while keeping pet insurance accessible.
International expansion represents another key growth opportunity. Under its five-year strategy, Trupanion has expanded into Europe, where relatively low pet-insurance penetration provides substantial long-term potential. As the subscriber base scales, greater operating leverage could support margin expansion and stronger free cash flow.
Trupanion is also broadening its addressable market through products such as Chewy and Aflac, which target lower- and mid-ARPU segments, alongside Firkin, Phi Direct, and offerings designed for continental Europe. The company has further expanded its technology platform through a branded offering and partnerships with automation providers in Germany and Switzerland.
With a strong capital position and solid operating performance, Trupanion can continue investing in product innovation and international expansion.
Optimistic Growth Estimates for TRUP
The Zacks Consensus Estimate for 2026 revenues and earnings indicates year-over-year improvement of 10.5% and 40%, respectively. The consensus estimate for 2027 revenues and earnings indicates year-over-year improvement of 8.7% and 10.6%, respectively. TRUP has a Growth Score of A.
Image Source: Zacks Investment Research
For 2026, the company expects revenues of $1.584-$1.601 billion, with the midpoint implying approximately 14% year-over-year growth. Adjusted operating income is expected in the range of $176-$184 million, representing about 19% growth at the midpoint.
Muted Analyst Sentiment on TRUP
The consensus estimate for 2026 and 2027 earnings witnessed no movement in the last 30 days.
The consensus estimates for LMND’s 2026 and 2027 earnings have witnessed no movement in the last 30 days. The same holds true for ROOT.
Parting Thoughts on TRUP Shares
TRUP is poised to grow in the fast-growing pet insurance market as pet ownership continues to increase and veterinary care costs rise. Its VGM Score of A instills confidence.
Given its premium valuation, muted analyst sentiment and narrowed guidance by management, it is better to adopt a wait-and-see approach for this Zacks Rank #3 (Hold) stock now. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.